Is ZIOP or DIVO a better dividend investment in 2026?

ZIOP currently yields 231.03% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: ZIOP offers higher current income.

What is the dividend yield difference between ZIOP and DIVO?

ZIOP has a forward dividend yield of 231.03% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 224.54 percentage points.

Home › Compare › ZIOP vs DIVO

ZIOP vs DIVO: Dividend Comparison 2026

ZIOP yields 231.03% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ZIOP wins by $281.96M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ZIOP

● Live price

231.03%

Share price

$0.87

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$281.99M

Annual income

$152,307,756.02

Full ZIOP calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — ZIOP vs DIVO

📍 ZIOP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ZIOP	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ZIOP + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ZIOP pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZIOP

Annual income on $10K today (after 15% tax)

$19,637.29/yr

After 10yr DRIP, annual income (after tax)

$129,461,592.62/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, ZIOP beats the other by $129,460,758.19/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZIOP + DIVO for your $10,000?

ZIOP: 50%DIVO: 50%

100% DIVO50/50100% ZIOP

Portfolio after 10yr

$141.01M

Annual income

$76,154,368.85/yr

Blended yield

54.01%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZIOP buys

DIVO buys

No recent congressional trades found for ZIOP or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricZIOPDIVO

Forward yield	231.03% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$281.99M ✓	$30.7K
Annual income after 10y	$152,307,756.02 ✓	$981.68
Total dividends collected	$267.75M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ZIOP vs DIVO ($10,000, DRIP)

Year	ZIOP Portfolio	ZIOP Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$33,803	$23,102.69	$11,349	$649.42	+$22.5K → ZIOP
2	$109,153	$72,984.41	$12,833	$688.83	+$96.3K → ZIOP
3	$337,052	$220,258.08	$14,459	$727.90	+$322.6K → ZIOP
4	$996,281	$635,635.69	$16,238	$766.49	+$980.0K → ZIOP
5	$2,821,960	$1,755,939.31	$18,179	$804.47	+$2.80M → ZIOP
6	$7,667,803	$4,648,304.92	$20,293	$841.71	+$7.65M → ZIOP
7	$20,008,593	$11,804,044.41	$22,591	$878.14	+$19.99M → ZIOP
8	$50,195,948	$28,786,753.46	$25,087	$913.65	+$50.17M → ZIOP
9	$121,203,020	$67,493,355.30	$27,791	$948.18	+$121.18M → ZIOP
10	$281,994,987	$152,307,756.02	$30,718	$981.68	+$281.96M → ZIOP

ZIOP vs DIVO: Complete Analysis 2026

ZIOP — Stock

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Full ZIOP Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this ZIOP vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZIOP vs SCHD ZIOP vs JEPI ZIOP vs O ZIOP vs KO ZIOP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.